Novocure · 18 hours ago
Territory Manager, Thoracic - Jacksonville, FL
Novocure is a company dedicated to extending the lives of people living with cancer, and they are seeking a Territory Manager (Thoracic) to oversee sales and account management within significant academic institutions and community oncology practices. The role focuses on developing and implementing territory account plans, executing corporate strategies, and identifying new business opportunities to enhance HCP prescribing in the territory.
BiotechnologyHealth CareMedical DeviceOncology
Responsibilities
Provide field-based sales and promotional activities directed to oncology health care professionals in oncology settings to all key stakeholders in each practice including medical oncologists and supporting staff
Development and implementation of territory account plans utilizing a collaborative team approach, meeting and exceeding sales targets and revenue goals
Excellence in execution of corporate and regional strategies within assigned geographic area resulting in achievement of business objectives
Responsible for identifying new business opportunities to build and grow HCP prescribing within approved labeling in the territory
Qualification
Required
Minimum of a bachelor's degree in a relevant field (e.g., Life Sciences, Business, Healthcare)
Field sales experience in oncology and/or complex therapeutics is required
3-5 years in Oncology sales with a track record of meeting or exceeding sales targets
Experience in selling to both academic centers and community practices
In-depth understanding of lung cancer, its treatments, and the oncology market a plus
Preferred
Basic understanding of the clinical aspects of lung cancer treatment
Comfort with utilizing and presenting technological solutions related to the device
Experience in market analysis and the ability to identify and capitalize on market opportunities
Benefits
Annual bonus
Restricted stock unit grant
Full range of benefits
Company
Novocure
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
Funding
Current Stage
Public CompanyTotal Funding
$1BKey Investors
Pharmakon AdvisorsJP Morgan ChaseBioPharma Credit
2024-05-02Post Ipo Debt· $100M
2020-11-09Post Ipo Debt· $150M
2020-11-05Post Ipo Debt· $575M
Recent News
2026-01-13
Company data provided by crunchbase